Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research : https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research


Novocure (NASDAQ: NVCR) today announced it has entered into a strategic alliance with the NYU Grossman School of Medicine’s Department of Radiation Oncology that provides a framework for

PerkinElmer Announces Financial Results for the Third Quarter of 2020: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer Announces Financial Results for the Third Quarter of 2020


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 4, 2020.



The Company reported

Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2020 financial results after the market closes

Acadia Healthcare Names Former Deloitte U.S. Chairman Michael J. Fucci to Board of Directors: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Names Former Deloitte U.S. Chairman Michael J. Fucci to Board of Directors


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that Michael J. Fucci has been appointed to serve as an independent director on its Board of Directors. Mr. Fucci’s appointment, which

Southwestern Health Resources and Humana Announce Value-Based Agreement in North Texas: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Southwestern Health Resources and Humana Announce Value-Based Agreement in North Texas


Southwestern Health Resources (SWHR) – the clinically integrated network for University of Texas Southwestern Medical Center (UT Southwestern), Texas Health Resources, and more than 5,000

Premier Inc. Honors Call to Freedom with National Award and $100,000 for Community Initiative : https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. Honors Call to Freedom with National Award and $100,000 for Community Initiative


Call to Freedom, a nonprofit organization focused on navigating a healthy path for victims of human trafficking, has received the 28th annual Monroe E. Trout Premier Cares Award and a $100,000 cash

Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020


Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020.



In connection with the earnings release

Dexcom Reports Third Quarter 2020 Financial Results: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports Third Quarter 2020 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2020.



Third Quarter 2020 Financial Highlights:




  • Revenue grew 26% versus the same

Dexcom Reports Third Quarter 2020 Financial Results: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports Third Quarter 2020 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2020.



Third Quarter 2020 Financial Highlights:




  • Revenue grew 26% versus the same

Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications

Agreement with UCHealth Expands Humana’s Medicare Advantage Provider Network in the Rocky Mountain Region : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Agreement with UCHealth Expands Humana’s Medicare Advantage Provider Network in the Rocky Mountain Region


UCHealth and Humana Inc. (NYSE: HUM), a leading health and well-being company, have signed an in-network agreement for UCHealth University of Colorado Hospital on the Anschutz Medical Campus in

First Approved Cancer Treatment for TGCT Included DILIsym Simulations in FDA Review: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
First Approved Cancer Treatment for TGCT Included DILIsym Simulations in FDA Review


DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that simulations

PFIZER REPORTS THIRD-QUARTER 2020 RESULTShttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
PFIZER REPORTS THIRD-QUARTER 2020 RESULTS


Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2020 and updated and tightened certain components of Total Company(3) 2020 financial guidance, which continues to reflect actual

PFIZER REPORTS THIRD-QUARTER 2020 RESULTShttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
PFIZER REPORTS THIRD-QUARTER 2020 RESULTS


Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2020 and updated and tightened certain components of Total Company(3) 2020 financial guidance, which continues to reflect actual

FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitishttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Priority Review designation to the company’s New Drug Application (NDA) for

FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitishttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Priority Review designation to the company’s New Drug Application (NDA) for

Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers


Regulatory News:



Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announced the detailed results from

Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue


DexCom, Inc. (NASDAQ:DXCM) today announced that Rick Doubleday, Executive Vice President and Chief Commercial Officer, will retire at the end of 2020 in order to spend more time with his family

Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue


DexCom, Inc. (NASDAQ:DXCM) today announced that Rick Doubleday, Executive Vice President and Chief Commercial Officer, will retire at the end of 2020 in order to spend more time with his family

Premier, Inc. Declares Quarterly Cash Dividend: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Declares Quarterly Cash Dividend


Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.19 per share of Class A common stock issued and

PerkinElmer erhält CE-Kennzeichnung für auf Atemwegsinfektionen, einschließlich COVID-19, ausgerichtetes Multi-Analyt-Panel: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer erhält CE-Kennzeichnung für auf Atemwegsinfektionen, einschließlich COVID-19, ausgerichtetes Multi-Analyt-Panel


PerkinElmer, Inc. (NYSE: PKI) meldete heute, dass sein PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel die Zulassung für die Vermarktung als In-vitro-Diagnostikum (IVD) in mehr als 30 Ländern im Sinne

ProvideGx® and Baxter Healthcare Secure the Supply of Critical Shortage Drug for COVID-19 Patients Requiring Ventilation: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
ProvideGx® and Baxter Healthcare Secure the Supply of Critical Shortage Drug for COVID-19 Patients Requiring Ventilation


Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Baxter Healthcare to supply pre-filled, single-use IV bags of dexmedetomidine hydrochloride to healthcare providers

Bayer kauft Asklepios: Wird jetzt alles besser?
Bayer kauft Asklepios: Wird jetzt alles besser?

Schon seit vielen Monaten steht die Aktie des Leverkusener Chemie- und Pharmagiganten Bayer (WKN: BAY001) unter Abgabedruck. Grund hierfür ist natürlich die leider völlig verkorkste

Bayer kauft Asklepios: Wird jetzt alles besser?
Bayer kauft Asklepios: Wird jetzt alles besser?

Schon seit vielen Monaten steht die Aktie des Leverkusener Chemie- und Pharmagiganten Bayer (WKN: BAY001) unter Abgabedruck. Grund hierfür ist natürlich die leider völlig verkorkste

PerkinElmer Receives CE Mark for Multi-analyte Respiratory Panel Including COVID-19 : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer Receives CE Mark for Multi-analyte Respiratory Panel Including COVID-19


PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30